In an up­date, Gilead spot­lights top-line hits amid a mixed set of PhII da­ta for its $600M NASH drug

Six months af­ter putting out some stel­lar ear­ly-stage da­ta from a study of its NASH drug GS-0976, Gilead has come back with the full slate of re­sults, un­der­scor­ing the po­ten­tial here as well as the chal­lenge ahead for re­searchers.

In the break­down, in­ves­ti­ga­tors point­ed to a dose-de­pen­dent re­sponse on two key mea­sures of the dis­ease, re­peat­ing a 43% re­duc­tion in liv­er fat among a small group of pa­tients tak­ing the high dose of the drug, in-li­censed from Nim­bus for a jaw-drop­ping $600 mil­lion in quick cash.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER